title: Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC.
abstract: OBJECTIVE
  A small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) is a 35 kDa protein involved in a number of biological processes. However, the role of SGTA in non-small-cell lung cancer (NSCLC) tumorigenesis has never been elucidated. The purpose of this study was to determine whether SGTA could serve as a biomarker for stratification and prediction of prognosis in NSCLC.
  
  
  METHODS
  Small glutamine-rich tetratricopeptide repeat-containing protein alpha expression was evaluated by Western blot in 8 paired fresh lung cancer tissues and immunohistochemistry on 83 paraffin-embedded sections. The effect of SGTA was assessed by RNA interference in A549 cells. Serum starvation and refeeding, flow cytometry, CCK-8, and tunnel assays were performed.
  
  
  RESULTS
  Small glutamine-rich tetratricopeptide repeat-containing protein alpha was highly expressed in NSCLC and significantly correlated with NSCLC histological differentiation, clinical stage, and Ki-67. Multivariate analysis indicated that SGTA was an independent prognostic factor for NSCLC patients' survival. The present investigation demonstrated that suppression of SGTA expression resulted in a significant decline of proliferation in A549 cells. Besides, SGTA could abolish the toxicity of cisplatin in A549 cells.
  
  
  CONCLUSIONS
  These findings suggested that SGTA might play an important role in promoting the tumorigenesis of NSCLC, and thus be a promising therapeutic target to prevent NSCLC progression.
authors.affiliation: Department of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
authors.forename: Qun
authors.initials: Q
authors.lastname: Xue
authors.forename: Liting
authors.initials: L
authors.lastname: Lv
authors.forename: Chunhua
authors.initials: C
authors.lastname: Wan
authors.forename: Buyou
authors.initials: B
authors.lastname: Chen
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.forename: Tingting
authors.initials: T
authors.lastname: Ni
authors.forename: Yifei
authors.initials: Y
authors.lastname: Liu
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Liu
authors.forename: Xia
authors.initials: X
authors.lastname: Cong
authors.forename: Yiqun
authors.initials: Y
authors.lastname: Zhou
authors.forename: Runzhou
authors.initials: R
authors.lastname: Ni
authors.forename: Guoxin
authors.initials: G
authors.lastname: Mao
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality; D000328:Adult; D000368:Aged; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality; D002352:Carrier Proteins / Q000378:metabolism*; D002453:Cell Cycle; D049109:Cell Proliferation; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008168:Lung / Q000378:metabolism; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D018832:Molecular Chaperones; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D018832:Molecular Chaperones; C114575:SGTA protein, human